In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving ...
Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
including CEO of obesity drugmaker Novo Nordisk, met with the government. Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S. President ...
Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.